TABLE 3.
Statistical tests of additive and multiplicative models.
| Drug A | Drug B | Adverse reaction | Additive model (α = 0.05) | Multiplicative model (α = 0.05) | ||
|---|---|---|---|---|---|---|
| δ | P | exp(δ) | P | |||
| sacubitril/valsartan | atorvastatin | rhabdomyolysis | 0.0004 | 0.8903 | 1.7047 | 0.2533 |
| myopathy | 0.0054 | 0.3700 | 1.6449 | 0.0193 | ||
| myositis | 0.0005 | 0.7163 | 5.6604 | 0.1153 | ||
| blood creatine phosphokinase increased | 0.0005 | 0.8657 | 0.7906 | 0.6087 | ||
| musculoskeletal discomfort | 0.0016 | 0.6245 | 1.5950 | 0.2263 | ||
| rosuvastatin | muscular weakness | −0.001 | 0.7623 | 1.0625 | 0.8381 | |
| myositis | −0.0001 | 0.9282 | 3.4998 | 0.2548 | ||
| blood creatine phosphokinase increased | −0.0002 | 0.8674 | 1.1860 | 0.8667 | ||
| simvastatin | musculoskeletal pain | 0.0106 | 0.0118 | 4.3445 | < 0.0001 | |
| myopathy | 0.0092 | 0.0995 | 1.8660 | 0.0034 | ||
| myositis | 0.0003 | 0.8259 | 4.0056 | 0.2005 | ||
| blood creatine phosphokinase increased | 0.0013 | 0.4218 | 3.9149 | 0.0616 | ||